James C. Clemmer - 19 Jul 2024 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role: President and CEO, Director
Signature: /s/ Stephen A. Trowbridge, as Attorney in Fact
Issuer symbol: ANGO
Transactions as of: 19 Jul 2024
Net transactions value: $0
Form type: 4
Filing time: 23 Jul 2024, 18:36:22 UTC
Previous filing: 19 Jul 2024
Next filing: 25 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANGO	Common Stock	Award	$0	+3,817	+0.6%	$0.000000	640,387	19 Jul 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANGO	Performance Right	Award	$0	+7,633		$0.000000	7,633	19 Jul 2024	Common Stock	7,633		Direct	F2
transaction	ANGO	Non-Qualified Stock Option (right to buy)	Award	$0	+7,466		$0.000000	7,466	19 Jul 2024	Common Stock	7,466	$7.18	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The acquisition of 3,817 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,817 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2025, such that 25% of the restricted stock units will vest on each of July 19, 2025, 2026, 2027 and 2028.
F2	Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
F3	These stock options vest in four equal annual installments beginning on July 19, 2025, such that 25% of the options will vest on each of July 19, 2025, 2026, 2027 and 2028.